From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 50s
Nanobiotix Cash Runway Meets Clinical Progress
Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress.
In brief
Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress. Nanobiotix's EUR 110.9 million cash runway funds operations through 2029 while advancing JNJ-1900 in head and neck cancer trials. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Quarterly Results
Nanobiotix reported EUR 5.6 million revenue for first half 2026.
“Nanobiotix reported revenue of EUR 5.6 million for the first half of 2026”
Revenue Drop
Revenue fell from EUR 26.4 million in first half 2025 to EUR 5.6 million in first half 2026.
“revenue of EUR 5.6 million for the first half of 2026, compared with EUR 26.4 million for the first half of 2025”
Net Loss
Net loss was EUR 34.3 million for first half 2026 versus EUR 5.4 million in first half 2025.
“net loss of EUR 34.3 million for the first half of 2026, compared with a net loss of EUR 5.4 million for the first half of 2025”
Cash Position
Cash and equivalents stood at EUR 110.9 million as of June 30, 2026.
“cash and cash equivalents of EUR 110.9 million at June 30, 2026”
Runway Timeline
Management expects cash to fund operations through 2029.
“this cash position was expected to fund operations into 2029”
Clinical Focus
JNJ-1900 progress in head and neck cancer trials remains key for value.
“the company continued to focus on advancing JNJ-1900 and supporting the Johnson & Johnson collaboration”
What matters most
Nanobiotix's EUR 110.9 million cash runway funds operations through 2029 while advancing JNJ-1900 in head and neck cancer trials.
